1. Home
  2. MCRB vs ACOG Comparison

MCRB vs ACOG Comparison

Compare MCRB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$8.65

Market Cap

139.7M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.01

Market Cap

129.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCRB
ACOG
Founded
2010
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
129.4M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
MCRB
ACOG
Price
$8.65
$6.01
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$14.33
$18.00
AVG Volume (30 Days)
93.5K
65.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
2.40
N/A
Revenue
$126,325,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$132.35
P/E Ratio
$3.43
N/A
Revenue Growth
1672.24
N/A
52 Week Low
$0.36
$3.75
52 Week High
$29.98
$10.88

Technical Indicators

Market Signals
Indicator
MCRB
ACOG
Relative Strength Index (RSI) 26.09 53.78
Support Level $7.12 $5.11
Resistance Level $8.49 $6.72
Average True Range (ATR) 1.13 0.62
MACD -0.42 0.12
Stochastic Oscillator 5.42 79.62

Price Performance

Historical Comparison
MCRB
ACOG

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: